Retatrutide 20mg Injection Pen (pre – Filled 3ml Cartridge) – Genlabs

Product Description

Retatrutide 20 mg (3 mL Cartridge) is a next-generation injectable medication currently under clinical investigation for the management of obesity, type 2 diabetes, and metabolic disorders. It is administered using a reusable injection pen, offering precision dosing and convenience. Retatrutide is drawing major attention because it targets three metabolic hormone receptors, setting it apart from existing weight-loss and diabetes therapies.
How It Works?
Genlabs Retatrutide is a triple-agonist peptide that activates the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. By simultaneously stimulating these three metabolic pathways, retatrutide helps reduce appetite and overall food intake, improves insulin sensitivity, enhances energy expenditure, and supports effective regulation of blood glucose levels.
This multi-hormonal approach leads to greater weight loss and metabolic improvement compared to single or dual-agonist medications.
Dosage :
Administered once weekly via subcutaneous injection. Begins with a low starting dose, gradually increased over several weeks to reduce side effects. The 20 mg / 3 mL cartridge allows for multiple dose adjustments using a reusable pen.
Exact dosing schedules vary based on individual tolerance, treatment goals, and study protocols.
Benefits :

Significant weight loss observed in clinical studies
Improved blood glucose control
Reduced insulin resistance
Decreased appetite and cravings
Potential improvement in cardiometabolic health
Convenient once-weekly injection
Reusable pen system minimizes waste and improves dosing accuracy

Side Effects :
Side effects may occur, especially during dose escalation like,

Nausea
Vomiting
Diarrhea
Constipation
Decreased appetite

Less common but serious risks:
Hypoglycemia (especially when combined with other diabetes medications)
Gastrointestinal intolerance
Possible increased heart rate
Long-term safety data is still being evaluated in ongoing clinical trials.
Conclusion :
Genlabs Retatrutide 20mg (3 mL Cartridge) represents a promising advancement in metabolic and weight-management therapies due to its triple-hormone mechanism of action. Early clinical results suggest superior effectiveness compared to existing treatments, particularly for obesity and type 2 diabetes. Howeve, it should only be used under proper medical guidance.